MedTrace Logo

Short Term Effect of Empagliflozin in Hypertension

NCT04203914 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-12-23

No results posted yet for this study

Summary

The investigators assessed the 6-week effect of once daily 25mg SGLT2-i Empagliflozin on left ventricular diastolic function and blood pressure profile in non diabetic hypertensive patients

Conditions

Interventions

DRUG

Empagliflozin Tablets

Add-on 25mg once daily

Sponsors & Collaborators

  • Yaounde Central Hospital

    lead OTHER_GOV

Principal Investigators

  • Jean Claude Mbanya, MD, PhD · University of Yaounde 1, Cameroon

  • Eugene Sobngwi, MD, PhD · University of Yaounde 1, Cameroon

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-10
Primary Completion
2017-05-30
Completion
2017-09-30

Countries

  • Cameroon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04203914 on ClinicalTrials.gov